Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Isabel Syndikus et al.|The Lancet Oncology|2019Cited by 643
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Paul Silcocks et al.|The Lancet Oncology|2014Cited by 374
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trialsAlicia Okines, Andrew Wotherspoon, David González de Castro et al.|European Journal of Cancer|2013Cited by 40